Inhalation Sciences signs new CRO contract worth 75 KEUR with returning global pharma client
(Stockholm, 22 June 2020) Inhalation Sciences (ISAB) has signed a new CRO (Contract Research) order worth 75 KEUR for a project using its in vitro lung simulation tool DissolvIt[®]. The contract is with a returning CRO client—a noted global pharma company. CEO Manoush Masarrat: “This new order from a returning client underlines the benefits DissolvIt[®] gives inhaled drug developers. The voluminous, precise data DissolvIt[® ]deliver are, quite simply, leading. It’s a world-class solution. This new order confirms it once again.”
Contract Research has long been an essential part of ISAB’s foundation—both scientifically and commercially. The company’s flagship inhalation R&D technologies, such as PreciseInhale®, DissolvIt® and intratracheal inhalation, were all refined and optimized through sustained commercial CR with clients. Throughout the current Coronavirus situation, revenues from CRO have remained robust.
CEO Manoush Masarrat “Our CRO services are crucial for us and our clients. They build long-term relationships and collaborations, demonstrating to new customers the outstanding capabilities of our technology. With today’s travel restrictions during the ongoing COVID-19 pandemic, ISAB’s CRO services have continued to be a high-value way to keep providing our customers with the leading data they need, and that today’s situation requires.”
The new Contract Research order will use ISAB’s in vitro simulation tool DissolvIt®. A leading in vitro solution within inhalation research, DissolvIt® has been in high demand since its commercial launch in Q1 2020, with three modules shipped to customers and new CR using the solution.
ISAB Director of Projects and in vitro specialist Maria Malmlöf: “We’re delighted to see DissolvIt® meets and even exceeds our own and our clients’ expectations. The IVIVC (In Vitro In Vivo Correlation) capabilities of DissolvIt® are leading, generating vital data, including Cmax and Tmax curves, that until now have not been able to be captured using conventional in vitro experiments. This new order again proves how much DissolvIt® is in demand.”
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.email@example.com Mobile: +46 (0)73 628 9153Press release in PDF format